Izinkulungwane zeziguli ezaqala nsuku zonke i-Saxenda manje sezibuza umbuzo ofanayo: ingabe yisikhathi sokuthuthela e-Wegovy kanye ngesonto, futhi ukushintsha kufanele kwenziwe kanjani ngokuphepha? Yomibili le mithi ingama-agonists e-GLP-1 receptor enziwe nguNovo Nordisk, kodwa isebenzisa ama-molecule ahlukene (liraglutide vs semaglutide), isigqi sedosi ehlukile kanye neshejuli ye-titration ehlukile. Ukuthola uguquko ngendlela efanele kuvikela ukubekezeleleka, kugcina umfutho wokwehla kwesisindo futhi kugwema amaphutha avamile njengokugqagqana kwezidakamizwa ezimbili.
Uma ufuna ukubheka ngqo ukuthi yisiphi isidakamizwa esifanele isiguli, bheka umhlahlandlela wethu wangaphambilini, Ukuqhathanisa i-Wegovy ne-Saxenda: Yimuphi Umuthi Wokunciphisa Isisindo Okulungele . Lesi sihloko sigxile kokuthile okuhlukile: inqubo engokoqobo yokushintsha usuka e-Saxenda uye ku-Wegovy, ehlanganisa isikhathi, umthamo wokuqala, i-titration kanye nalokho iziguli nemitholampilo okufanele ikulindele ezinyangeni zokuqala.
Kungani Iziguli Zisuka E-Saxenda Ziya E-Wegovy
Izizathu ezivame kakhulu odokotela bacabangele inguquko ye-Saxenda iye ku-Wegovy yilezi:
Ukwehla kwesisindo esimaphakathi. Esivivinyweni se-STEP 8 okungahleliwe, abantu abadala abangenaso isifo sikashukela balahlekelwe isilinganiso esingu-15.8% sesisindo somzimba ku-semaglutide 2.4 mg masonto onke uma kuqhathaniswa no-6.4% ku-liraglutide 3.0 mg nsuku zonke emasontweni angama-68 (Rubino et al., JAMA 2022).
Imijovo embalwa. Umjovo owodwa ngesonto esikhundleni sesikhombisa wenza ukubambelela kube lula kubantu abaningi.
Ithafa eliseSaxenda. Ilebula ye-Saxenda yeluleka ukuyeka ukwelashwa uma umuntu omdala engalahlekelwanga okungenani u-4% wesisindo esiyisisekelo ngemva kwamasonto angu-16, okwenza abaningi abanikeza imithi ukuba babuyekeze ezinye izindlela.
Ukunikezwa, izindleko noma izinguquko zomshwalense , ezihluka ngezwe futhi zishintsha njalo.
Ukushintsha akuphoqelekile. Isiqondiso sokuguqulwa kwe-US Veterans Affairs siphawula ukuthi asikho isidingo sokuguqula isiguli esenza kahle futhi esilahlekelwa isisindo ku-liraglutide. Isinqumo kufanele ngaso sonke isikhathi sibe umuntu ngamunye.
I-Saxenda vs i-Wegovy Dosing ngokubuka nje
Ngokusho kolwazi olusemthethweni lwase-US oluchazayo:
I-Saxenda (liraglutide) ijova ngaphansi kwesikhumba kanye ngosuku . Iqala ku-0.6 mg ngosuku isonto elilodwa futhi ikhuphuke ngo-0.6 mg isonto ngalinye (1.2 mg, 1.8 mg, 2.4 mg) kuze kube yilapho umthamo wesondlo wansuku zonke ongu-3 mg ufinyelelwa evikini lesi-5. Imithamo ephansi ingeye-titration kuphela.
Umjovo we-Wegovy (semaglutide) unikezwa ngaphansi kwesikhumba kanye ngesonto , ngosuku olufanayo isonto ngalinye. Ishejuli yokukhuphuka ithi:
Ilebula yamanje yase-US iphinde ivumele abantu abadala abaye babekezelela i-2.4 mg okungenani amasonto angu-4 ukuze bakhuphuke baze bafike ku-7.2 mg masonto onke lapho ukwehla kwesisindo okuqhubekayo kuboniswa emtholampilo. Imithamo namandla atholakalayo ayahluka ngezwe, ngakho hlala ulandela ilebula yendawo. Ukuze uthole isizinda sokuthi i-semaglutide isebenza kanjani, funda Ukuqonda Injection ye-Semaglutide kanye nokusetshenziswa kwayo.
Womabili amalebula athi umuthi akufanele uhlanganiswe nanoma iyiphi enye i-GLP-1 receptor agonist. Lowo mthetho owodwa ulolonga yonke inqubo yokushintsha.
Ungashintsha Kanjani Ukusuka eSaxenda uye ku-Wegovy: Isinyathelo ngesinyathelo
I-Wegovy noma ilebula ye-Saxenda ayiqukethe iphrothokholi esemthethweni yokushintsha i-Saxenda-to-Wegovy. Okulandelayo kubonisa isiqondiso somtholampilo esishicilelwe kanye nokwenza okuvamile. Umyali uhlala enza ucingo lokugcina.
Isinyathelo 1: Buyekeza Isizathu Sokushintsha
Odokotela baqinisekisa kuqala ukuthi kungani isiguli sifuna ukushintsha, kungakhathaliseki ukuthi lokho kusebenza kahle, ukunethezeka, izindleko noma imiphumela emibi. Bese bahlola kabusha ama-contraindications. I-Wegovy akufanele isetshenziswe ezigulini ezinomlando womuntu siqu noma womndeni we-medullary thyroid carcinoma noma i-MEN 2, futhi abantu abanesifo sikashukela sohlobo 2 badinga ukuqapha i-glucose ngesikhathi soshintsho.
Isinyathelo sesi-2: Isikhathi - Akukho Ukugeza Okudingekayo
Umhlahlandlela osebenzayo oshicilelwe ku- Clinical Diabetes (Almandoz, Lingvay and Morales, 2020) uphakamisa ukuthi isiguli esibekezelela i-agonist ye-GLP-1 nsuku zonke ngethamo eligcwele singaqala i-ejenti yamasonto onke ngosuku olulandela umthamo wokugcina wansuku zonke . I-Christchurch Medicines Information Service (2025) yaseNew Zealand nayo ithi asikho isikhathi sokuwasha esidingekayo. Ukuthatha zombili izidakamizwa ndawonye akunconywa ngaphansi kwanoma iyiphi ilebula.
Kukhona okuhlukile. Uma ukushintsha kwenzeka ngenxa yemiphumela emibi yesisu, isiqondiso esifanayo seluleka ukuthi kumiswe i-Saxenda futhi kulindwe kuze kube yilapho izimpawu ziphela ngaphambi kokuqala i-Wegovy ngethamo layo eliphansi kakhulu.
Isinyathelo sesi-3: Khetha Umthamo Wokuqala
Imithamo ye-Liraglutide 3 mg nsuku zonke kanye ne-semaglutide ayishintsheki ngokuqondile, futhi akukho ukulingana okuqinisekisiwe. Amathebula okuguqulwa ashicilelwe athatha indlela elandelanayo:
Iziguli eziku-Saxenda 0.6–1.2 mg nsuku zonke: ngokuvamile i-Wegovy iqala ngo- 0.25 mg masonto onke.
Iziguli ku-1.8-2.4 mg nsuku zonke: 0.25 mg noma 0.5 mg ngesonto.
Iziguli zizinzile ku-3 mg nsuku zonke: ezinye izinsizakalo (VA, CMIS) ziphakamisa u-0.5 mg masonto onke njengendawo yokuqala engaphandle kwelebula.
Kusukela ku-0.25 mg, njengoba ilebula ye-Wegovy incoma, kuhlala kuyinketho eqaphe kakhulu futhi eqondaniswe nelebula.
Isinyathelo sesi-4: Khuphuka Njalo Emavikini angu-4
Kusukela kumthamo wokuqala, i-Wegovy yenyuka njalo emavikini ama-4 ukuya ku-1.7 mg noma ku-2.4 mg. Uma umthamo ungabekezeleleki kahle, ilebula ivumela ukukhuphuka okulandelayo ukubambezeleka ngamaviki angu-4. Kumithamo egejiwe, ilebula ithi uma umthamo owodwa ugejiwe futhi olandelayo ungaphezu kwezinsuku ezi-2, kufanele uthathwe ngokushesha ngangokunokwenzeka. Uma imithamo emibili noma ngaphezulu elandelanayo yeqiwe, ukukhuphuka kabusha kwethamo eliphansi kungase kudingeke.
Yini Ongayilindela Ngemva Kwenguquko
I-Gastrointestinal Side Effects
Isicanucanu, isifo sohudo, ukuhlanza kanye nokuqunjelwa yimiphumela emibi kakhulu yayo yomibili le mithi. KUSINYATHELO 8, izehlakalo zesisu zibikwe yi-84.1% yabasebenzisi be-semaglutide kanye nama-82.7% wabasebenzisi be-liraglutide, ikakhulukazi abamnene ukuya kokulinganisela. Kodwa-ke, abahlanganyeli abambalwa bayeke i-semaglutide (13.5%) kune-liraglutide (27.6%). Ukudla okuncane, ukuyeka ukudla lapho ugcwele nokuhlala ugcwele amanzi kusiza iziguli eziningi ngesinyathelo ngasinye somthamo omusha.
I-Weight-Loss Trajectory
Ngenxa yokuthi umthamo wokuqala we-Wegovy uphansi, ezinye iziguli zibona ukubuya kancane kwesifiso sokudla emasontweni okuqala ngemva kokuyeka u-3 mg we-Saxenda. Lokhu kuvame ukuxazulula njengoba umthamo ukhuphuka. KUSINYATHELO 8, u-70.9% wabahlanganyeli ku-semaglutide bathole ukwehla kwesisindo esingu-10%, uma kuqhathaniswa nama-25.6% ku-liraglutide. Imiphumela isancike ekudleni, emisebenzini nakubhayoloji yomuntu ngamunye.
Izinguquko Zobuso Nomzimba
Ukushesha, ukuncipha kwesisindo okujulile kungase kwembule ukwehla kwevolumu emathempelini, ezihlathini nasemihlathini, lokho okubizwa 'ubuso be-Ozempic'. Imitholampilo yobuhle iya ngokuya ibhanqa iziguli ezilawula isisindo nemithi yokubuyisela esimweni. Isihloko sethu Ingabe Ama-Deermal Fillers Angakwazi Ukubuyisela Ubuso Be-Ozempic? Izimbangela Nezinketho Zokwelashwa zichaza izinketho.
Amaphutha Ajwayelekile Lapho Ushintsha Ukusuka ku-Saxenda kuya ku-Wegovy
Ukweqa izidakamizwa zombili. Ungathathi umthamo wokugcina we-Saxenda ngosuku olufanayo nomjovo wokuqala we-Wegovy.
Yeqa iqonde ku-2.4 mg. Ukweqa i-titration kuphakamisa ubungozi bokusabela okunzima kwe-GI kanye nokulimala kwezinso okuhlobene nokuphelelwa amandla kwamanzi.
Ukuphatha imithamo ngokulinganayo. I-3 mg ye-liraglutide 'ayifani' nanoma yimuphi umthamo othile we-semaglutide.
Ukuziba imithi yesifo sikashukela. Iziguli ezisebenzisa i-insulin noma i-sulfonylurea zingadinga ukulungiswa komthamo ukuze kugwenywe i-hypoglycemia.
Ukusebenzisa imikhiqizo 'semaglutide' engalawulwa. Iziguli kufanele zisebenzise kuphela imikhiqizo egunyaziwe, enqunyiwe evela kumakhemisi asemthethweni.
Kusho Ukuthini Lokhu Ngemitholampilo Nabasabalalisi
Emitholampilo yobuhle nokuphila kahle, ukukhuphuka kokwelashwa kwe-GLP-1 kwamasonto onke kuwulolonga kabusha uhambo lwesiguli. Iziguli ekulawulweni kwesisindo sokwelashwa zivame ukufuna izindlela zokwelapha eziguqula umzimba, izinga lesikhumba kanye nokubuyisela umthamo ngesikhathi sohlelo lwazo. Uhlolojikelele lwethu lwe Amathrendi aphezulu Wokuguquguquka Komzimba Ongahlinzeki kanye Nokulawulwa Kwesisindo samamephu wango-2026 lapho isidingo sihamba khona.
Amabhrendi nabasabalalisi abakha iphothifoliyo yokulawula isisindo kufanele babhangqe ukunakekelwa kwe-GLP-1 kwencwadi kadokotela kuphela, ehlala ngaphansi kokuqondisa kwezokwelapha, nemikhiqizo ehambisanayo efana nezigcwalisi, izikhuthazi ze-collagen, i-mesotherapy nemijovo eguqula umzimba. Ukuze uqonde ukuthi ubudlelwano belebula yangasese busebenza kanjani, funda Ukuhlola Imijovo Yokunciphisa Isisindo se-OEM: Ithuba Elibalulekile Lebhizinisi Lezempilo Nokuphila kahle . I-AOMA isekela ozakwethu ngokukhiqiza okusekelwe ku-GMP, imibhalo elawulayo kanye nokufaka uphawu ngokwezifiso.
FAQ
Ngingakwazi ukuqala i-Wegovy ngosuku olulandela umjovo wami wokugcina we-Saxenda?
Ezimweni eziningi, yebo. Isiqondiso esishicilelwe sithi akukho ukugeza okudingekayo, futhi i-ejenti yangeviki ingaqala ngosuku olungemva komthamo wokugcina wansuku zonke. Uma ushintsha ngenxa yemiphumela engemihle, udokotela wakho angase akucele ukuthi ulinde kuze kube yilapho izimpawu seziphelile.
Imuphi umthamo we-Wegovy okufanele ngiqale ngawo ngemva kwe-Saxenda 3 mg?
Ilebula ye-Wegovy iqala wonke umuntu ku-0.25 mg masonto onke. Ezinye izinsizakalo zomtholampilo zibheka u-0.5 mg ngaphandle kwelebula ezigulini ezinzile ku-Saxenda 3 mg. Udokotela wakho unquma ngokusekelwe ekubekezeleleni kwakho.
Ngingakwazi ukuthatha i-Saxenda ne-Wegovy ndawonye?
Cha. Womabili amalebula asho ukuthi ukuwahlanganisa nanoma iyiphi enye i-GLP-1 receptor agonist akunconywa.
Kuthatha isikhathi esingakanani ukufinyelela umthamo ogcwele we-Wegovy?
Ukusuka ku-0.25 mg, ukufika ku-2.4 mg kuthatha amasonto ayi-16, nokugcinwa kusuka evikini le-17. Ukuqala ku-0.5 mg kufinyeza lokhu ngamaviki angu-4.
Ingabe i-Wegovy isebenza kakhulu kune-Saxenda?
Esivivinyweni se-STEP 8 ikhanda-to-head, i-semaglutide 2.4 mg ikhiqize isilinganiso se-15.8% sokulahlekelwa isisindo ngokumelene ne-6.4% nge-liraglutide 3.0 mg emavikini angu-68. Imiphumela ngayinye iyahlukahluka.
Umshwana Wokuzikhipha Emthwalweni Wezempilo
Lesi sihloko sihloselwe izinjongo zemfundo jikelele kanye nezokunakekelwa kwezempilo nezingcweti zemboni. Akusona iseluleko sezokwelapha. I-Saxenda kanye ne-Wegovy imithi kadokotela kuphela. Noma iluphi ushintsho ekwelapheni, okuhlanganisa isikhathi kanye nomthamo, kufanele kunqunywe umnikezeli onelayisensi ngokolwazi lwendawo lwendawo. I-AOMA ayikhi noma ithengisi i-Saxenda noma i-Wegovy, okuyizimpawu zokuthengisa ze-Novo Nordisk A/S.
Izithenjwa
Rubino DM, Greenway FL, Khalid U, et al. Umthelela we-subcutaneous semaglutide vs i-liraglutide yansuku zonke esisindweni somzimba kubantu abadala abakhuluphele ngokweqile noma abakhuluphele abangenaso isifo sikashukela: i-STEP 8 isilingo somtholampilo esingahleliwe. JAMA . 2022;327(2):138-150. I-PMID: 35015037.
Almandoz JP, Lingvay I, Morales J, et al. Ukushintsha phakathi kwe-glucagon-like peptide-1 receptor agonists: okunengqondo kanye nesiqondiso esisebenzayo. Isifo sikashukela i-Clin . 2020;38(4):390-402. PMID: 33132510.
I-WEGOVY (semaglutide) umjovo/amaphilisi, Ulwazi Lokuchazwa kwe-US, i-Novo Nordisk (DailyMed, ibuyekezwe ngoJuni 2026).
Umjovo we-SAXENDA (liraglutide), US Prescribing Information, Novo Nordisk (DailyMed / FDA, 2026).
UMnyango Wezindaba Zomakadebona wase-US. I-Semaglutide (WEGOVY) isiqondiso sokuguqulwa komjovo ongaphansi kwesikhumba sokuphathwa kwesisindo, February 2023.
Christchurch Medicines Information Service. Ukushintsha kusuka ku-liraglutide (Saxenda) kuya ku-semaglutide (Wegovy), Julayi 2025.
